ABBV · News · 20261031N
Acquisition / Partnership / Divestiture
AbbVie Inc. · 2026-10-31 · Importance 42 · Surprise 48 · In source text
AbbVie acquired Apogee, according to the Q3 key-facts report. The acquisition adds late-stage immunology assets to AbbVie's portfolio. The report did not disclose the transaction value or timing details.
Key facts
- AbbVie acquired Apogee, adding late-stage immunology assets. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | AbbVie acquired Apogee, adding late-stage immunology assets. |